

## Market Analysis of Cancer and Oncology Research

### Michael

PhD in Experimental Physics, University of Chicago, Visiting Prof. in Medical Oncology, University of Texas, San Antonio, USA, E-mail: michael.retsky@gmail.com

Cancer is the second leading cause of death globally, and about 1 in 6 deaths is due to cancer. It is estimated that 7.6 million deaths due to cancer in the year 2005 by WHO (world health organization), this number expected to rise to 12 million deaths by the year 2030. Up to 2001, Malaysia did not have a National Cancer Registry (NCR) to estimate the real incidence of cancer among Malaysians. Evaluation of NCR reports indicates that the number of new cancer cases among residents in Peninsular Malaysia has decreased from 26,089 to 21,773. After taking this report into account unregistered cases, the probability that a Malaysian will get cancer in his/her life time is 1 in 4. Since Lifestyle changes such as lack of regular exercise, consumption of a high fat diet, and breast feeding habits are reported as some important risk factors among Malaysian breast cancer patients.

This report studies the global market size of Cancer Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Drugs in these regions, this report categorizes the global Cancer Drugs market by players/brands, region, type and application and also studies the global market status, competition landscape, growth rate, future trends, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

The aim of this study are to define, segment, and project the size of the Cancer Drugs market based on company, product type, application and key regions. The various contributors involved in the value chain of Cancer Drugs include manufacturers, suppliers, distributors, intermediaries, and customers.

